MeiraGTx (MGTX) versus Its Competitors Head to Head Review

MeiraGTx (NASDAQ:MGTX – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare MeiraGTx to related businesses based on the strength of its analyst recommendations, institutional ownership, risk, dividends, earnings, valuation and profitability.

Profitability

This table compares MeiraGTx and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MeiraGTx 19.46% 85.23% 24.12%
MeiraGTx Competitors -12,224.09% -202.33% -31.23%

Institutional and Insider Ownership

67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 7.4% of MeiraGTx shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares MeiraGTx and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
MeiraGTx $81.39 million -$114.20 million 11.47
MeiraGTx Competitors $730.68 million $10.35 million -18.82

MeiraGTx’s competitors have higher revenue and earnings than MeiraGTx. MeiraGTx is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

MeiraGTx has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, MeiraGTx’s competitors have a beta of -1.84, indicating that their average share price is 284% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for MeiraGTx and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MeiraGTx 0 3 5 0 2.62
MeiraGTx Competitors 9919 15313 45657 1602 2.54

MeiraGTx presently has a consensus price target of $24.00, suggesting a potential upside of 161.44%. As a group, “Biotechnology” companies have a potential upside of 126.41%. Given MeiraGTx’s stronger consensus rating and higher probable upside, equities analysts clearly believe MeiraGTx is more favorable than its competitors.

Summary

MeiraGTx beats its competitors on 8 of the 13 factors compared.

MeiraGTx Company Profile

(Get Free Report)

MeiraGTx Holdings plc is a biotechnology company developing gene therapies for serious diseases with limited treatment options. Its research focuses on using adeno-associated virus (AAV) vectors to deliver genetic material to target cells, including in programs for inherited retinal diseases, neurological conditions and salivary gland dysfunction. The company also develops manufacturing capabilities and technologies intended to support the production of gene therapies. MeiraGTx was founded in 2015 and has operations in the United States and the United Kingdom.

Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.